DIFFLAM

This brand name is authorized in Australia, Cyprus, Hong Kong SAR China, Ireland, Malta, New Zealand, Singapore, UK.

Active ingredients

The drug DIFFLAM contains one active pharmaceutical ingredient (API):

1	Benzydamine UNII K2GI407R4Q - BENZYDAMINE HYDROCHLORIDE
	Benzydamine exerts an anti-inflammatory and analgesic action by stabilising the cellular membrane and inhibiting prostaglandin synthesis.
	Read more about Benzydamine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DIFFLAM Lozenge	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A01AD02	Benzydamine	A Alimentary tract and metabolism → A01 Stomatological preparations → A01A Stomatological preparations → A01AD Other agents for local oral treatment
Discover more medicines within A01AD02
M01AX07	Benzydamine	M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AX Other antiinflammatory and antirheumatic agents, non-steroids
Discover more medicines within M01AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1121B, 5032W, 5385K
GB	Medicines & Healthcare Products Regulatory Agency	19973, 19980, 19983, 20001, 20064, 371518, 371522, 371525, 371527
HK	Department of Health Drug Office	31754, 36674, 42365, 56223, 56224
MT	Medicines Authority	AA908/03203, MA1507/00401, MA1507/00402, PI521/08601A, PI770/17101A, PI908/03201A, PI908/03204A
NZ	Medicines and Medical Devices Safety Authority	11774, 4017, 4020
SG	Health Sciences Authority	04232P, 07411P, 13625P, 13626P